Q-omics provides the consensus-scored PCDH18 profile across patient tissues and cancer cell-line models. PCDH18 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PCDH18 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, PCDH18 RNA expression shows 18,527 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, BLCA, and THYM as cancer lineages where PCDH18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDH18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDH18 survival associations across molecular data types. PCDH18 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDH18 RNA expression–survival associations across cancer types. High PCDH18 expression shows unfavorable associations in KIRP, BLCA, ACC, CESC and LGG, but favorable associations in UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PCDH18 RNA expression.
This table summarizes PCDH18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PCDH18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDH18 shows lower tumor expression in BLCA, KIRP, UCEC, BRCA and KIRC and higher tumor expression in STAD. The BLCA box plot shows higher PCDH18 RNA expression in normal versus tumor tissue (log2 FC = −1.532, t-test p = .003).
This table shows molecular features associated with PCDH18 in patient tissues and cancer cell lines. In patient samples, PCDH18 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDH18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and CNS.
